Polycythemia Vera Presenting as Tinnitus and Hearing Loss: A Case Report

How Kit Thong1,*, Kim Yen Goh2, Aminuddin Bin Saim1,3

1Department of Otorhinolaryngology, Head and Neck Surgery Faculty of Medicine, KPJ Healthcare University College, Negeri Sembilan, Malaysia; 2Department of Clinical Haematology and Stem Cell Transplant, KPJ Ampang Puteri Specialist Hospital, Selangor, Malaysia; 3Department of Otorhinolaryngology, Head and Neck Surgery, KPJ Ampang Puteri Specialist Hospital, Selangor, Malaysia

Introduction

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by erythrocytosis and commonly associated with the JAK2 V617F mutation. PV, essential thrombocythemia (ET), and primary myelofibrosis (PMF) belong to the same group of Philadelphia chromosome-negative MPNs [1]. PV is a relatively rare disease with a prevalence rate of 22 per 100,000. Historically, hearing impairments were first described as a complication of PV in 1963, and it was stated that symptoms recovered after a phlebotomy. Occlusion and thrombosis of the feeding labyrinthine artery causing cochlear ischemia were thought to be the cause of such symptoms and complaints.

BACKGROUND: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) characterized by erythrocytosis and commonly associated with the JAK2 V617F mutation. PV is a relatively rare disease with a prevalence rate of 22 per 100,000. Historically, hearing impairments were first described as a complication of PV in 1963, and it was stated that symptoms recovered after a phlebotomy. Occlusion and thrombosis of the feeding labyrinthine artery causing cochlear ischemia were thought to be the cause of such symptoms and complaints.

CASE PRESENTATION: We are reporting a case of PV that was presented in our ENT outpatient clinic. The patient presented with a main complaint of sudden-onset bilateral tinnitus with one-sided hearing loss. The patient was treated medically with hydroxyurea, aspirin, and phlebotomy. On improvement of the hematological parameters, the patient noted an improvement in his hearing and it was confirmed with the finding on the repeated hearing assessment.

CONCLUSION: This case emphasizes the importance of otolaryngologists remaining vigilant and maintaining a high index of suspicion as PV can present with audiological symptoms. The early diagnosis and initiation of treatment can improve patients’ hearing and reduce the morbidity of such patients.

Case Report

A 55-year-old gentleman presented with bilateral tinnitus and left-sided hearing loss that had been present for a month at our outpatient clinic. The symptoms occurred acutely and were not associated with otalgia, otorrhea, or dizziness. There was no previous history of acoustic trauma, otologic trauma, or drug intake. The patient denied any underlying chronic illnesses or comorbidities. His family history was negative for any hematological malignancies or hereditary hearing loss. On physical examination, both the external ear canal and tympanic membrane appeared normal. There was no facial nerve palsy or ophthalmoplegia. A nasal endoscopy was performed, nasopharynx and bilateral eustachian tube were found

to be normal. The tuning fork test showed a bilateral positive Rinne’s test with no lateralization on Weber’s test. Other systemic examinations were unremarkable.

Investigations showed a hemoglobin of 20.5 g/dL, a packed cell volume of 61%, platelet counts of $403 \times 10^3$/uL, a total white blood cell count of $11.1 \times 10^3$/uL, and an erythrocyte sedimentation rate of 1 mm/hr. Pure tone audiometry showed normal hearing in the right ear and mild to moderately severe sensorineural hearing loss with downsloping over a high frequency with an average hearing level of 45 db (Figure 1). Tympanometry was performed and revealed Type A in both ears, which signifies normal middle ear pressure and function. Magnetic resonance imaging (MRI) of the brain and cerebellopontine angle was also performed which was reported as normal with no evidence of cerebellopontine angle mass.

The patient was subsequently referred to the department of hematology and oncology. Further investigation revealed erythrocytosis and thrombocytosis on peripheral blood smears and a decreased level of erythropoietin 3.0 mU/mL. The patient was tested positive for the JAK2 V6617F mutation. Based on two major criteria (hemoglobin 20.5 g/dL and the patient being JAK V6617F mutation positive) with one minor criteria (erythropoietin level of 3 mU/L), a diagnosis of PV was made. The patient was started on 500 mg of hydroxyurea twice daily, 100 mg of aspirin daily, and a phlebotomy was performed 3 times over a period of 6 months. After 5 months of treatment, a review of the blood analysis was as follows: Hemoglobin was at 15.8 g/dL, hematocrit was 48%, and the platelet count was 305,000/mcL. A repeated audiogram noted improvement in the left ear hearing at the higher frequency (Figure 2). The patient also reported a reduction in the intensity of the tinnitus. Tinnitus was also subjectively measured using the tinnitus handicap inventory score. On presentation, the score was 74/100; the second score was 68/100 after 9 weeks of treatment when the hemoglobin level was 15.4 g/dL with a packed cell volume of 45%. The

![Figure 1: Pure tone audiometry on the first visit](image1)

![Figure 2: Pure tone audiometry on post-treatment](image2)
patient was followed up on regularly by our team and the hematology department. *Ginkgo biloba* at a 150 mg dosage twice daily was subsequently initiated, and the patient reported improvements in the intensity of tinnitus with a score of 58/100.

**Discussion**

The classification for hematopoietic neoplasm was recently revised in 2016. It recognizes MPN as a part of the myeloid malignancies. MPN includes PV, ET, and PMF [5]. PV is the most common among the group of MPN with an incidence of 0.01–2.61/100,000 and a prevalence of 0.49–46.88/100,000. The 5-year relative survival of PV was reported to be as high as 84.8% [6]. The diagnosis of PV is based on the revised World Health Organization criteria of three major or the first major and one minor criteria. The major criteria include (1) hemoglobin >16.5 g/dL in men and >16.0 g/dL in women or hematocrit >49% in men and >48% women or increased red blood cell mass, (2) hypercellular bone marrow with trilineage growth, and (3) positive JAK2 mutation. The minor criterion is subnormal serum erythropoietin [5]. Common clinical symptoms range from mild non-specific complaints of pruritus, headache, weakness, and dizziness to severe complications of thrombosis and hemorrhaging. The reported incidence of thrombotic complications such as stroke, acute myocardial infarction, and pulmonary embolism in PV is between 13 and 60%. Hemorrhagic complications include epistaxis, gastrointestinal hemorrhage, or ecchymosis. ENT symptoms of tinnitus, hearing loss, vertigo, and facial weakness are also associated with the disease. Hearing loss and tinnitus are the most commonly reported otological symptoms [7], [8]. Outcomes of such symptoms vary with some patients experiencing significant improvement [9]. The pathophysiology of hearing loss in patients with PV is caused by an elevated hematocrit, increased red blood cell mass, high viscosity, and increased acute-phase reactants causing thrombosis in small vessels such as the labyrinthine artery. Both thrombosis and increased viscosity cause microvascular occlusion and were accepted as the primary cause of symptoms in PV. In a study by Dogan *et al.*, patients with known PV were compared to healthy controls. Cochlear impairment was found to be significantly more common in PV group (p = 0.004) [10].

Kim *et al.* reported a case of PV which presented with symptoms of vertigo and on physical examination demonstrated gaze-evoked nystagmus. Similarly seen in our case, the findings and symptoms disappeared on normalizing of the blood parameters with repetitive phlebotomy and medical therapy of hydroxyurea and aspirin. The author also postulated that the pathophysiology of vertigo in PV could be explained by central vestibulopathy due to vascular insufficiency rather than peripheral vestibulopathy caused by inner ear vascular hypertoviscosity [11].

However, hearing loss and tinnitus as initial reporting symptoms are rare, and no cases were found during a search of the PubMed archives. Before the conclusion of PV associated hearing loss in our patient, other organic causes of asymmetrical sensorineural hearing loss including acoustic neuroma were ruled out. PV is a chronic incurable disease with a reasonably good 5-year survival rate of 85%. However, a detailed and thorough workup is needed to reduce the rate of misdiagnosis due to the conflation of patients with ET and PV. Phlebotomy is the primary treatment for PV. It can effectively lower the hematocrit to <45% in males and <42% in females, which will effectively reduce the risk of developing PV complications of thrombosis [1].

A recently published guideline on the management of PV by Tefferi *et al.* proposed a risk stratification system in the treatment approach of patients with PV. The main objective in the treatment of both patients with PV and ET is prevention of potential thrombohemorrhagic complications. All patients with PV are advised for phlebotomy to maintain the hematocrit level below 45% and once or twice daily aspirin. In the very low-risk ET/PV group, patients might not require therapy while aspirin therapy is advised for those with low-risk disease. Cytoreductive therapy, however, is recommended only for high-risk ET and PV. The drug of choice for cytoreductive therapy, in both ET and PV, is hydroxyurea and second-line drugs of choice are interferon-α and busulfan [12]. For our patient, phlebotomy was performed 3 times during the initial 6 months of therapy. The patient was also started on long-term hydroxyurea therapy and aspirin for prophylaxis of thrombosis with phlebotomy performed periodically to keep hematocrit <45%. The duration of treatment will be determined by the hemat-oncology team based on close monitoring of symptoms and clinical response.

Ruxolitinib, a JAK 1 and JAK 2 selective inhibitor, is still being evaluated as a treatment option in view of the high rate of JAK2 mutations in patients with PV. At present, ruxolitinib has been approved by the US Food and Drug Administration for the treatment of patients with intermediate- and high-risk myelofibrosis or those with an inadequate response or are intolerant of hydroxyurea [11]. For our patient, after the phlebotomy was performed, the laboratory values of hemoglobin and hematocrit improved to normal limits. The patient noted that there were improvements in the tinnitus; however, his hearing did not recover to normal even though significant improvements were noted on the repeated pure tone audiometric tests post-treatment. A longer duration of follow-up is needed to determine the long-term outcome of PV on hearing loss and tinnitus in the patient.

**Conclusion**

We presented a case of a newly diagnosed PV patient with an unusual initial presentation of
tinnitus and hearing loss. This case emphasizes the importance of otolaryngologists remaining vigilant and maintaining a high index of suspicion as PV can present with audiological symptoms. The early diagnosis and initiation of treatment can improve patients’ hearing and reduce the morbidity of such patients.

References